Concepedia

William M. Sallas

WM

12

Publications

887

Citations

12

H-Index

1981

Active since

Affiliations

Novartis (United States)(Current)

Novartis (Switzerland)

Tris Pharma (United States)

William M. Sallas is an author at Novartis (United States) specializing in medicine, pharmacology, and statistics.

Top concepts

Publications per year

1981–2018

12

Publications

12

Vildagliptin, a Dipeptidyl Peptidase-IV Inhibitor, Improves Model-Assessed β-Cell Function in Patients with Type 2 Diabetes

Andrea Mari, William M. Sallas, Yanling He et al. · The Journal of Clinical Endocrinology & Metabolism · 2005 · 361 citations · Full text

A mechanism‐based binding model for the population pharmacokinetics and pharmacodynamics of omalizumab

Naoto Hayashi, Yuko Tsukamoto, William M. Sallas et al. · British Journal of Clinical Pharmacology · 2006 · 168 citations · Full text

Nilotinib population pharmacokinetics and exposure-response analysis in patients with imatinib-resistant or -intolerant chronic myeloid leukemia

Francis J. Giles, Ophelia Yin, William M. Sallas et al. · European Journal of Clinical Pharmacology · 2012 · 85 citations

, , +9

Best Linear Recursive Estimation for Mixed Linear Models

William M. Sallas, David A. Harville · Journal of the American Statistical Association · 1981 · 59 citations

, , +10

The effect of food consumption on lumefantrine bioavailability in African children receiving artemether-lumefantrine crushed or dispersible tablets (Coartem<sup>®</sup>) for acute uncomplicated<i>Plasmodium falciparum</i>malaria

Steffen Borrmann, William M. Sallas, Sónia Machevo et al. · Tropical Medicine & International Health · 2010 · 53 citations

Rows per page

1–5 of 12